Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:gene_therapy
|
| gptkbp:clinicalTrialPhase |
Phase 2
Phase 1b |
| gptkbp:deliveredBy |
stereotactic neurosurgical infusion
|
| gptkbp:developedBy |
gptkb:Voyager_Therapeutics
|
| gptkbp:indication |
gptkb:Parkinson's_disease
|
| gptkbp:mechanismOfAction |
delivers AADC gene to brain
|
| gptkbp:region |
gptkb:Europe
gptkb:United_States |
| gptkbp:result |
improved motor function
|
| gptkbp:routeOfAdministration |
intracerebral
|
| gptkbp:status |
investigational
|
| gptkbp:targetGene |
Aromatic L-amino acid decarboxylase (AADC)
|
| gptkbp:treatment |
AAV-based gene therapy
|
| gptkbp:trialSponsor |
gptkb:Voyager_Therapeutics
gptkb:Neurocrine_Biosciences |
| gptkbp:vectorFor |
AAV2
|
| gptkbp:bfsParent |
gptkb:Voyager_Therapeutics
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
VY-AADC
|